People and partners

PharmaFutures will explore the key trends reshaping healthcare and the circumstances under which innovation can be harnessed to improve productivity and efficiency in health systems. The dialogue focuses on three geographies: Europe, Emerging Economies, the United States and concludes with a global overview. The first dialogue is on Europe and involves the following participants:

PharmaFutures Working Group 2012

  • Mr Stewart Adkins, Stewart Adkins Advisors Ltd, Director
  • Mr Mark Becker, Healthcare Analyst, Fidelity International
  • Dr Scott Braunstein, Managing Director, JP Morgan Asset Management
  • Mr Jim Easton, National Director for Improvement and Efficiency, UK Department of Health
  • Mr Joel Emery, Independent
  • Ms Charlotte Ersbøll, Corporate Vice President, Global Stakeholder Engagement, Novo Nordisk
  • Mr Eddie Gray, President, Pharmaceuticals Europe, Glaxo SmithKline
  • Dr Jane Griffiths, Company Group Chairman, Janssen Pharmaceuticals EMEA, Johnson & Johnson
  • Mr Graham Hetherington, Chief Financial Officer, Shire plc
  • Mr Simon Jose, President of Stiefel, Glaxo SmithKline
  • Ms Natasha Landell-Mills, Senior Analyst, USS
  • Prof Sir Michael Rawlins, Chariman, NICE
  • Dr Jack Scannell, Analyst, Stanford C. Bernstein & Co., LLC
  • Mr John Schaetzl, Industry Commentator, Independent
  • Dr Ad Schuurman, President, MEDEV
  • Mr Carl Seiden, President, Seiden Pharmaceutical Strategies
  • Dr Divya Srivastava, Health Economist, OECD
  • Mr Dan Summerfield, Co-Head Responsible Investment, USS
  • Dr Giorgia Valsesia, Healthcare Analyst, SAM Research AG
  • Mr Stijn Vanacker, Analyst Global Healthcare, Robeco

European Workshop Additional Participants

  • Dr Rafael Bengoa, Minister for Health and Consumer Affairs in the Basque Country, Basque Government
  • Dr Anna Bucsics, Vice Department Head, Department of Pharmaceuticals, Association of Austrian Social Security Institutions
  • Dr Angela Coulter, Director of Global Initiatives, Foundation for Informed Medical Decision-making
  • Mr Thomas Heynisch, Deputy Head of Unit, DG Enerprise and Industry, European Commission
  • Mr Bo Wesley, Senior Specialist, Innovation and Effectiveness, Novo Nordisk

Emerging Economies Workshop Additional Participants

tbc.

US Workshop Additional Participants

tbc.

 

 

Comments

John Schaetzl

I have watched the industry suffer the loss of public trust, struggle with bringing new products to market and lose the ability to grow its top line. This perfect storm is reflected in the current share price and as a long term investor I hope to hear and perhaps help find the early signs of a path to recovery.

John Schaetzl, Independent